CMStatistics 2022: Start Registration
View Submission - CMStatistics
Title: Modelling chronic kidney disease: the GLOMMS2 cohort Authors:  Gordon Prescott - University of Central Lancashire (United Kingdom) [presenting]
Simon Sawhney - University of Aberdeen (United Kingdom)
Corri Black - University of Aberdeen (United Kingdom)
Angharad Marks - University of Aberdeen (United Kingdom)
Nick Fluck - NHS Grampian (United Kingdom)
Laura Clark - NHS Grampian (United Kingdom)
Adeera Levin - University of British Columbia (Canada)
Abstract: The Grampian Laboratory Outcomes Morbidity and Mortality Study II (GLOMMS2) is a population cohort of 70,000 adults in a single UK health authority in North-East Scotland (population 440,000). It links national and regional data sources on kidney function, comorbidities and major healthcare events (hospital episodes, renal replacement therapy and death) over time. Uniquely, all biochemistry data are processed by a single laboratory service regardless of clinical location, minimising the loss of baseline and follow-up data. The cohort includes around 20,000 with chronic kidney disease (CKD) and 20,000 with normal kidney function. Research by Aberdeen Applied Renal Research Collaboration has included the prediction of mortality, the need for renal replacement therapy within five years, renal progression, and the intermediate and 10-year prognosis of those who suffer episodes of acute kidney injury.GLOMMS2 is one of 34 multinational cohorts contributing to the CKD Prognosis Consortium. Data from more than 5 million individuals have been used to develop risk models for multiple renal outcomes. Health cohorts may be structured around regular health check data, interactions at times of poor health, or a mixture. An overview of research on the GLOMMS2 cohort will be presented. The methodological complications of combining cohorts will be discussed.